Association between phosphate and long-term outcome in CAD patients underwent coronary intervention

Tsung Ying Tsai, Pai Feng Hsu*, Cheng Hsueh Wu, Ya Ling Yang, Su Chan Chen, Shao Sung Huang, Wan Leong Chan, Shing Jong Lin, Jaw Wen Chen, Ju Pin Pan, Min Ji Charng, Ying Hwa Chen, Tao Cheng Wu, Tse Min Lu, Po Hsun Huang, Hao Min Cheng, Chin Chou Huang, Shih Hsien Sung, Yenn Jiang Lin, Hsin Bang Leu

*此作品的通信作者

研究成果: Article同行評審

3 引文 斯高帕斯(Scopus)

摘要

Phosphate has been linked to higher cardiovascular (CV) risk. However, whether phosphate is associated with poor outcomes for patients with coronary artery disease (CAD) after percutaneous coronary interventions (PCIs) remained undetermined. 2,894 CAD patients (2,220 male, aged 71.6 ± 12.2), who received PCI at TVGH from 2006 to 2015, with phosphate measurement, were enrolled. The primary outcome was the composite of major adverse CV events [MACE, comprising of CV death, nonfatal MI, and nonfatal stroke] and heart failure hospitalization (HHF). The key secondary outcome was MACE. There was a J-curve association between phosphate and CV events after adjusted for comorbidities and renal function. Phosphate around 3.2 ± 0.1 mg/dL was associated with the lowest CV risk. In Cox analysis, each 1 mg/dL increases in phosphate was associated with a higher risk of MACE + HHF (HR: 1.12, 95% CI: 1.05–1.21): CV death (HR: 1.37, 95% CI: 1.22–1.55) and HHF (HR: 1.12, 95% CI: 1.02–1.23). Subgroup analyses showed more prominent association between phosphate and MACE + HHF in male, age > 65, bare-metal stents (BMSs), LVEF < 50%, eGFR < 60, LDL > 70 mg/dL, and emergent PCI. Phosphate has a significant association with the risk of CV events in CAD patients undergoing PCI that was independent of comorbidities and renal function.

原文English
文章編號20080
期刊Scientific reports
11
發行號1
DOIs
出版狀態Published - 12月 2021

指紋

深入研究「Association between phosphate and long-term outcome in CAD patients underwent coronary intervention」主題。共同形成了獨特的指紋。

引用此